Exhibit 99.1
ILLUMINA REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2005
Product and Service Revenue Increases 42% Over Second Quarter 2004
SAN DIEGO, CALIFORNIA, July 26, 2005 — Illumina, Inc. (NASDAQ: ILMN) announced today its financial
results for the second quarter of 2005.
Total revenue for the quarter was $15.8 million, which represents a 38% increase compared to total
revenue of $11.5 million, recorded in the second quarter of 2004. Product and service revenue was
$15.4 million, representing a 42% increase over the second quarter of 2004.
The Company reported a net loss of $18.5 million, or $0.46 per basic and diluted share, for the
second quarter of 2005 compared to a net loss of $3.5 million, or $0.10 per basic and diluted
share, in the second quarter of 2004. The Company’s net loss per basic and diluted share in the
second quarter of 2005 included a one-time charge of $0.39 per basic and diluted share related to
the write-off of $15.8 million of acquired in-process research and development in connection with
the Company’s acquisition of CyVera Corporation in April 2005. Excluding this one-time charge, net
loss for the quarter was $2.7 million, or $0.07 per basic and diluted share.
Gross margins for products and services in the quarter were 69.3%, compared to 71.8% for the second
quarter in 2004. Selling, general and administrative expense increased to $6.5 million compared to
$6.0 million in the prior year’s period. Research and development expenses increased to $7.3
million compared to $5.3 million in the second quarter of 2004.
Highlights since our last quarterly conference call include:
| • |
|
Commenced commercial shipments of the
Sentrix® whole-genome genotyping BeadChips and
our new Infinium™ assay protocol; |
| • |
|
Achieved our 16th consecutive quarter of sequential revenue growth; |
| • |
|
Shipped a record 18 BeadStations during the quarter, bringing our total number of Beadlabs and
BeadStations shipped to 82; |
| • |
|
Booked 21 genotyping service contracts; |
| • |
|
Launched new SNP panels to query the MHC region of the genome — the most gene-rich area of any
chromosomal region and an area that is directly implicated in inflammatory and autoimmune diseases
such as multiple sclerosis and diabetes; |
| • |
|
Named Christian Henry as our Vice President, Chief Financial Officer and promoted Kirk Malloy,
Ph.D., to the new position of Vice President, Customer Solutions; and |
| • |
|
Received two new patents, bringing our total to 39 issued or allowed and 107 pending, including
those acquired with CyVera. |
These highlights underscore Illumina’s strategy of building a comprehensive offering of scalable,
multi-application systems. At the foundation of our systems are the Sentrix(R) Array
Matrix, the Sentrix BeadChip, the BeadArray Reader and our
Oligator® DNA synthesis
capability. The BeadStation system addresses moderate-throughput requirements and complements
Illumina’s production-scale BeadLab. Both systems can be scaled in multiple dimensions, providing
customers the flexibility to perform SNP genotyping or gene expression experiments on the same
platform, with content ranging from whole genomes to focused sets, at various levels of throughput
and automation and industry-leading cost per sample. Illumina is also developing a portfolio of
powerful assay technologies to deliver even further benefit to BeadArray™
technology.
Financial Outlook
For fiscal 2005 we expect total revenue to range from $70 million to $76 million. We expect net
loss per basic and diluted share to range from $0.16 to $0.06, excluding the impact of the $0.39
charge related to the write-off of acquired in-process research and development in connection with
the CyVera acquisition. Including this charge, our net loss per basic and diluted share is
anticipated to range from $0.55 to $0.45.
For the third quarter 2005, the Company expects total revenue to range between $18 million and $20
million. Net loss per share is anticipated to range between $0.06 and $0.03 per basic and diluted
share.
Conference Call Information
A conference call has been scheduled for 2:00 p.m. Pacific Time today to discuss Illumina’s second
quarter 2005 results as well as 2005 guidance. Individuals may listen to the call by dialing
800-324-5531 (international callers should dial +1 312 461-1932) or by accessing the live webcast
under the “Investors” tab of Illumina’s website at:
www.illumina.com.
About Illumina
Illumina (www.illumina.com) is developing next-generation tools for the large-scale analysis of
genetic variation and function. The Company’s proprietary BeadArray technology — now used in
leading genomics centers around the world — provides the throughput, cost effectiveness and
flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to
perform the billions of tests necessary to extract medically valuable information from advances in
genomics and proteomics. This information will help pave the way to personalized medicine by
correlating genetic variation and gene function with particular disease states, enhancing drug
discovery, allowing diseases to be detected earlier and more specifically, and permitting better
choices of drugs for individual patients.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release
may contain forward-looking statements that involve risks and uncertainties. Among the important
factors that could cause actual results to differ materially from those in any forward-looking
statements are the costs and outcome of Illumina’s litigation with Affymetrix, the Company’s
ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis
output and technology to satisfy market demand deriving from the Company’s collaboration with
Invitrogen, Illumina’s ability to further develop and commercialize its BeadArray technologies and
to deploy new gene expression and genotyping products and applications for its platform technology,
to manufacture robust
Sentrix®
arrays and
Oligator® oligonucleotides, and
other factors detailed in the Company’s filings with the Securities and Exchange Commission
including its recent filings on Forms 10-K and 10-Q or in information disclosed in public
conference calls, the date and time of which are released beforehand. Illumina disclaims any
intent or obligation to update these forward-looking statements beyond the date of this release.
ILLUMINA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
(Unaudited)
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three months ended |
|
|
Six months ended |
|
| |
|
July 3, |
|
|
June 27, |
|
|
July 3, |
|
|
June 27, |
|
| |
|
2005 |
|
|
2004 |
|
|
2005 |
|
|
2004 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
$ |
12,636 |
|
|
$ |
9,045 |
|
|
$ |
24,801 |
|
|
$ |
17,984 |
|
Service |
|
|
2,783 |
|
|
|
1,815 |
|
|
|
5,474 |
|
|
|
2,965 |
|
Research |
|
|
405 |
|
|
|
626 |
|
|
|
697 |
|
|
|
1,340 |
|
| |
|
|
|
|
Total revenue |
|
|
15,824 |
|
|
|
11,486 |
|
|
|
30,972 |
|
|
|
22,289 |
|
| |
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
|
4,734 |
|
|
|
3,067 |
|
|
|
9,333 |
|
|
|
5,869 |
|
Research and development |
|
|
7,301 |
|
|
|
5,320 |
|
|
|
13,179 |
|
|
|
10,496 |
|
Selling, general and administrative |
|
|
6,494 |
|
|
|
5,993 |
|
|
|
12,487 |
|
|
|
11,731 |
|
Amortization of deferred compensation and
other non-cash compensation charges |
|
|
41 |
|
|
|
250 |
|
|
|
98 |
|
|
|
568 |
|
Litigation judgment |
|
|
— |
|
|
|
189 |
|
|
|
— |
|
|
|
378 |
|
In Process R&D |
|
|
15,800 |
|
|
|
— |
|
|
|
15,800 |
|
|
|
— |
|
| |
|
|
|
|
Total costs and expenses |
|
|
34,370 |
|
|
|
14,819 |
|
|
|
50,897 |
|
|
|
29,042 |
|
| |
|
|
|
|
| |
Loss from operations |
|
|
(18,546 |
) |
|
|
(3,333 |
) |
|
|
(19,925 |
) |
|
|
(6,753 |
) |
| |
Interest and other income (expense), net |
|
|
7 |
|
|
|
(183 |
) |
|
|
151 |
|
|
|
(694 |
) |
| |
|
|
|
|
| |
Net loss |
|
$ |
(18,539 |
) |
|
$ |
(3,516 |
) |
|
$ |
(19,774 |
) |
|
$ |
(7,447 |
) |
| |
|
|
|
|
| |
Net loss per share, basic and diluted |
|
$ |
(0.46 |
) |
|
$ |
(0.10 |
) |
|
$ |
(0.50 |
) |
|
$ |
(0.22 |
) |
| |
|
|
|
|
| |
Shares used in calculating net loss per share,
basic and diluted |
|
|
40,187 |
|
|
|
34,960 |
|
|
|
39,267 |
|
|
|
33,754 |
|
| |
|
|
|
|
================================================================================
ILLUMINA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
| |
|
|
|
|
|
|
|
|
| |
|
July 3, |
|
|
January 2, |
|
| |
|
2005 |
|
|
2005 |
|
| |
|
(unaudited) |
|
|
(Note) |
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and investments |
|
$ |
54,566 |
|
|
$ |
66,994 |
|
Accounts Receivable, net |
|
|
12,192 |
|
|
|
11,891 |
|
Inventory, net |
|
|
5,157 |
|
|
|
3,807 |
|
Other current assets |
|
|
1,023 |
|
|
|
999 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
72,938 |
|
|
|
83,691 |
|
Property and equipment, net |
|
|
13,573 |
|
|
|
8,574 |
|
Goodwill |
|
|
2,315 |
|
|
|
— |
|
Other assets, net |
|
|
2,433 |
|
|
|
2,642 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
91,259 |
|
|
$ |
94,907 |
|
|
|
|
|
|
|
|
| |
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
$ |
15,067 |
|
|
$ |
13,091 |
|
Litigation judgment |
|
|
— |
|
|
|
5,957 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
15,067 |
|
|
|
19,048 |
|
Long-term debt and liabilities |
|
|
5,903 |
|
|
|
3,597 |
|
Stockholders’ equity |
|
|
70,289 |
|
|
|
72,262 |
|
|
|
|
|
|
|
|
Total liabilities and stockholders’ equity |
|
$ |
91,259 |
|
|
$ |
94,907 |
|
|
|
|
|
|
|
|
Note: The Balance Sheet at January 2, 2005 has been derived from the audited financial
statements as of that date.
# # #
| |
|
|
|
|
|
|
|
|
Contacts:
|
|
Jay Flatley
|
|
Christian Henry
|
|
|
President & CEO
|
|
VP and Chief Financial Officer
|
|
|
1.858.202.4501 |
|
1.858.202.4508 |
|
|
jflatley@illumina.com
|
|
chenry@illumina.com
|
